Header

UZH-Logo

Maintenance Infos

Immunotherapy for glioblastoma: concepts and challenges


Weiss, T; Weller, M; Roth, P (2015). Immunotherapy for glioblastoma: concepts and challenges. Current Opinion in Neurology, 28(6):639-646.

Abstract

PURPOSE OF REVIEW Immunotherapy is an emerging treatment strategy against various cancer types including glioblastoma. It comprises different strategies to induce, boost or restore an antitumor immune response. This review provides an overview of recent preclinical and clinical developments in the field of immunotherapy against glioblastoma. We elucidate the concepts and challenges and point out the strengths and weaknesses of the most promising immunotherapeutic approaches. RECENT FINDINGS Immunotherapy is one of the most active research areas in glioblastoma. Data from preclinical work as well as phase I and phase II clinical trials revealed that immunotherapy against glioblastoma is overall well tolerated and able to promote a potent antitumor immune response. Among the therapeutic approaches that are currently under investigation, vaccination, for example, against the variant III of epidermal growth factor receptor, as well as immune checkpoint inhibition targeting receptors such as cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1, are among the most promising and advanced treatment strategies. However, there are considerable challenges to overcome such as the identification of novel target molecules for vaccination, appropriate patient selection criteria, strategies to prevent or handle immune-related adverse events, and the implementation of immunotherapy in multimodal treatment regimens together with conventional treatment strategies. SUMMARY Key features of immunotherapy are target specificity, adaptability, and durability. Results from preclinical assessments and clinical trials applying immunotherapy alone or in combination with conventional treatment options are promising. However, intense research and stringent clinical development are required to optimize the available treatment options and to overcome potential pitfalls.

Abstract

PURPOSE OF REVIEW Immunotherapy is an emerging treatment strategy against various cancer types including glioblastoma. It comprises different strategies to induce, boost or restore an antitumor immune response. This review provides an overview of recent preclinical and clinical developments in the field of immunotherapy against glioblastoma. We elucidate the concepts and challenges and point out the strengths and weaknesses of the most promising immunotherapeutic approaches. RECENT FINDINGS Immunotherapy is one of the most active research areas in glioblastoma. Data from preclinical work as well as phase I and phase II clinical trials revealed that immunotherapy against glioblastoma is overall well tolerated and able to promote a potent antitumor immune response. Among the therapeutic approaches that are currently under investigation, vaccination, for example, against the variant III of epidermal growth factor receptor, as well as immune checkpoint inhibition targeting receptors such as cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1, are among the most promising and advanced treatment strategies. However, there are considerable challenges to overcome such as the identification of novel target molecules for vaccination, appropriate patient selection criteria, strategies to prevent or handle immune-related adverse events, and the implementation of immunotherapy in multimodal treatment regimens together with conventional treatment strategies. SUMMARY Key features of immunotherapy are target specificity, adaptability, and durability. Results from preclinical assessments and clinical trials applying immunotherapy alone or in combination with conventional treatment options are promising. However, intense research and stringent clinical development are required to optimize the available treatment options and to overcome potential pitfalls.

Statistics

Citations

10 citations in Web of Science®
11 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

181 downloads since deposited on 04 Dec 2015
130 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:22 September 2015
Deposited On:04 Dec 2015 09:47
Last Modified:11 Dec 2017 07:25
Publisher:Lippincott Williams & Wilkins
ISSN:1080-8248
Additional Information:This is a non-final version of an article published in final form in Current Opinion in Neurology.
Publisher DOI:https://doi.org/10.1097/WCO.0000000000000249
PubMed ID:26402401

Download

Download PDF  'Immunotherapy for glioblastoma: concepts and challenges'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 209kB
View at publisher
Download PDF  'Immunotherapy for glioblastoma: concepts and challenges'.
Preview
Content: Published Version
Filetype: PDF
Size: 425kB
Filetype: Other (Coversheet Pages conversion from application/pdf to application/pdf)